Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design

Reuters

Yesterday

Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design

Oncolytics Biotech Inc. plans to wind down its GOBLET gastrointestinal study and reallocate resources toward registration-focused and registration-enabling programs for pelareorep in squamous cell anal cancer (SCAC) and metastatic colorectal cancer $(CRC)$. The company expects to meet with the U.S. Food and Drug Administration in mid-April to align on the design of a U.S.-based single-arm SCAC registrational study, which it believes could enroll well under 100 patients. Oncolytics will stop further enrollment in the GOBLET Cohort 5 metastatic pancreatic ductal adenocarcinoma arms at about 20 patients per arm, continue following enrolled patients, and report results when the data mature.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240900PRIMZONEFULLFEED9659818) on February 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2613178457"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613178457\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613178457?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613178457","market":"fut","top_or_hot":-1,"title":"Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ONCWF\">Oncolytics Biotech Inc.</a> plans to wind down its GOBLET gastrointestinal study and reallocate resources toward registration-focused and registration-enabling programs for pelareorep in squamous cell anal cancer (SCAC) and metastatic colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a>. The company expects to meet with the U.S. Food and Drug Administration in mid-April to align on the design of a U.S.-based single-arm SCAC registrational study, which it believes could enroll well under 100 patients. Oncolytics will stop further enrollment in the GOBLET Cohort 5 metastatic pancreatic ductal adenocarcinoma arms at about 20 patients per arm, continue following enrolled patients, and report results when the data mature.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ONCY\">Oncolytics Biotech Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240900PRIMZONEFULLFEED9659818) on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ONCWF\">Oncolytics Biotech Inc.</a> plans to wind down its GOBLET gastrointestinal study and reallocate resources toward registration-focused and registration-enabling programs for pelareorep in squamous cell anal cancer (SCAC) and metastatic colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a>. The company expects to meet with the U.S. Food and Drug Administration in mid-April to align on the design of a U.S.-based single-arm SCAC registrational study, which it believes could enroll well under 100 patients. Oncolytics will stop further enrollment in the GOBLET Cohort 5 metastatic pancreatic ductal adenocarcinoma arms at about 20 patients per arm, continue following enrolled patients, and report results when the data mature.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ONCY\">Oncolytics Biotech Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240900PRIMZONEFULLFEED9659818) on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL3Tj1fl:1","article_id":"2613178457","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613178457","pubTimestamp":1771941677,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design. Oncolytics Biotech Inc. plans to wind down its GOBLET gastrointestinal study and reallocate resources toward registration-focused and registration-enabling programs for pelareorep in squamous cell anal cancer  and metastatic colorectal cancer . The company expects to meet with the U.S. Food and Drug Administration in mid-April to align on the design of a U.S.-based single-arm SCAC registrational study, which it believes could enroll well under 100 patients. Oncolytics will stop further enrollment in the GOBLET Cohort 5 metastatic pancreatic ductal adenocarcinoma arms at about 20 patients per arm, continue following enrolled patients, and report results when the data mature.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","ONCY":"Oncolytics Biotech Inc","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC"},"translate_title":"Oncolytics Biotech将优先考虑以注册为重点的肛门和结直肠癌研究，逐步减少GOBLET招募，并寻求FDA对SCAC试验设计的协调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ONCY":0.9},"content_text":"Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design\n    \n\nOncolytics Biotech Inc. plans to wind down its GOBLET gastrointestinal study and reallocate resources toward registration-focused and registration-enabling programs for pelareorep in squamous cell anal cancer (SCAC) and metastatic colorectal cancer $(CRC)$. The company expects to meet with the U.S. Food and Drug Administration in mid-April to align on the design of a U.S.-based single-arm SCAC registrational study, which it believes could enroll well under 100 patients. Oncolytics will stop further enrollment in the GOBLET Cohort 5 metastatic pancreatic ductal adenocarcinoma arms at about 20 patients per arm, continue following enrolled patients, and report results when the data mature.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240900PRIMZONEFULLFEED9659818) on February 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}